Raul Santos: International Collaborative Insights into the Treatment of Homozygous FH
Raul Santos, Researcher at ARO Hospital Israelita Albert Einstein, shared on LinkedIn about a recent article he and his colleagues co-authored, adding:
“The therapy of Homozygous FH (HoFH) is a great challenge due to the extreme elevated LDL-C levels and the genetic variability that characterizes this disease.
Combination therapy is the rule to reduce LDL-C, and is classified in medications that depend on the LDL receptor function like statins, ezetimibe and PCSK9 inhibitors and those who are independent like Lomitapide and Evinacumab.
In this collaborative study between Canada, South Africa and Brazil led by John Mancini we showed that statins also reduce LDL-C by mechanisms other than depending on the LDL receptor alone.
HoFH is a devastating disease that needs to be diagnosed and treated ASAP.
Novel therapies are coming and hopefully will change for good how we treat this disease!”
Article: Assessment of LDL receptor-dependent lipid lowering therapies in patients with homozygous familial hypercholesterolemia according to functional genotype.
Authors: G.B.John Mancini, Arnold Ryomoto, Isabelle Ruel, Iulia Iatan, Jacques Genest, Frederick J. Raal, Raul D. Santos, Ana Paula Marte, Brooke A. Kennedy, Liam R. Brunham, Daniel Gaudet, Miriam Larouche, Diane Brisson, Robert A. Hegele
Read the Full Article on Atherosclerosis
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 12, 2026, 14:18Jean Jacques Kiladjian: Grateful to the MSH for the invitation to ‘Highlights of ASH’ in Asia-Pacific 2026
-
Apr 12, 2026, 14:15Paritosh Garg: A fibrotic marrow is not always PMF
-
Apr 12, 2026, 14:13Scott Woller: ACC/AHA Guidelines and the Role of Pulmonary Embolism Response Teams
-
Apr 12, 2026, 13:55Ifeanyichukwu Ifechidere: When Fibrinogen isn’t Really Fibrinogen
-
Apr 12, 2026, 13:53Alan Nurden: A Contemporary Update on the Pathogenesis of Inherited Platelet Dysfunction
-
Apr 12, 2026, 13:47Kalyan Roy: Visual Inspection of Blood Bags and Blood Products
-
Apr 12, 2026, 13:44Francisco Ujueta: PAD VS CAD – Why Individualized Antithrombotic Strategies Matter
-
Apr 12, 2026, 13:42William Aird: Anemia of Inflammation Not Just a Trade-Off but a Possible Compensation
-
Apr 12, 2026, 13:38Emmanuel J Favaloro: D-dimer testing in VTE diagnostic management studies